A major research gap: The use of anticoagulants in cirrhosis

Area of Science:

• Hepatology
• Thrombosis Research
• Pharmacology

Background:

• Historically, anticoagulants were avoided in cirrhosis due to bleeding risks.
• Emerging evidence suggests cirrhosis patients face prothrombotic risks, like portal vein thrombosis.
• This challenges the traditional view of a hypercoagulable state in cirrhosis.

Purpose of the Study:

• To review preclinical and clinical data on anticoagulant use in cirrhosis.
• To explore potential benefits including reduced liver fibrosis, portal hypertension, and improved survival.
• To discuss current challenges and future research directions for anticoagulation in cirrhosis.

Main Methods:

• Review of preclinical studies on anticoagulants in liver fibrosis models.
• Analysis of clinical data investigating anticoagulant efficacy and safety in cirrhosis.
• Examination of specific patient populations, such as those with atrial fibrillation and portal vein thrombosis.

Main Results:

• Preclinical data show promising effects of anticoagulants on liver fibrosis and portal hypertension.
• Clinical translation has faced challenges, with limited large-scale trial data.
• Anticoagulation may be beneficial in select cirrhosis patients, but risks require careful consideration.

Conclusions:

• Anticoagulation in cirrhosis warrants further investigation beyond traditional bleeding concerns.
• Randomized-controlled trials are essential to define the role of anticoagulants in managing cirrhosis.
• Optimizing anticoagulant therapy could improve outcomes for specific cirrhosis-related complications.